Oleg V. Leonov

Oleg V. Leonov

Auto-generated profile, based on publicly available information

Oleg V. Leonov

Clinical Oncology Center

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
Reinhard DummerReinhard Dummer
Reinhard Dummer
GLGeorgina Venetia Long
Georgina Venetia Long
Caroline RobertCaroline Robert
Caroline Robert
HTHussein A. Tawbi
Hussein A. Tawbi
KFKeith T. Flaherty
Keith T. Flaherty
DSDirk Schadendorf
Dirk Schadendorf
PURPOSE: Preclinical data suggest the combination of an anti–programmed death receptor 1 antibody plus dabrafenib and trametinib to have superior antitumor activity compared with dabrafenib plus trametinib alone. These observations are supported by translational evidence suggesting that immune checkpoint inhibitors plus targeted therapy may improve treatment outcomes in patients with BRAF V600–mutant metastatic melanoma. COMBI-i is a phase III trial evaluating spartalizumab, an anti–programmed death receptor 1 antibody, in combination with dabrafenib and trametinib (sparta-DabTram), versus placebo plus dabrafenib and trametinib (placebo-DabTram) in patients with BRAF V600–mutant unresectable or metastatic melanoma.METHODS: Patients received spartalizumab 400 mg intravenously every 4 weeks plus dabrafenib 150 mg orally twice daily and trametinib 2 mg orally once daily or placebo-DabTram. Participants were age ≥ 18 years with unresectable or metastatic BRAF V600–mutant melanoma. The primary end point was investigator-assessed progression-free survival. Overall survival was a key secondary end point (ClinicalTrials.gov identifier: NCT02967692 ).RESULTS: At data cutoff (July 1, 2020), the median progression-free survival was 16.2 months (95% CI, 12.7 to 23.9 months) in the sparta-DabTram arm versus 12.0 months (95% CI, 10.2 to 15.4 months) in the placebo-DabTram arm (hazard ratio, 0.82 [95% CI, 0.66 to 1.03]; P = .042 [one-sided; nonsignificant]). The objective response rates were 69% (183 of 267 patients) versus 64% (170 of 265 patients), respectively. Grade ≥ 3 treatment-related adverse events occurred in 55% (146 of 267) of patients in the sparta-DabTram arm and 33% (88 of 264) in the placebo-DabTram arm.CONCLUSION: The study did not meet its primary end point; broad first-line use of sparta-DabTram is not supported by these results. Further biomarker-driven investigation may identify patient subpopulations who could benefit from checkpoint inhibitor plus targeted therapy combinations.

4 May 2021 in Cancer Urology
Verified
Journal Article
Open access
PDF file
YYYu. N. Yurgel
Yu. N. Yurgel
BAB. Ya. Alekseev
B. Ya. Alekseev
EKE. I. Kopyltsov
E. I. Kopyltsov
OLO. V. Leonov
O. V. Leonov
ISI. A. Sikhvardt
I. A. Sikhvardt
НЮН. Ю. Юргель
Н. Ю. Юргель
Background. Intraoperative rectal injury in patients undergoing prostatectomy is a severe complication, worsens the quality of life and leads to social maladjustment.Objective. To develop, substantiate the reproducibility and safety of the technique for the formation of fascial duplication in the elimination of damage to the anterior rectal wall during prostatectomy.Materials and methods. The authors present a description of the technique and their own experience of retropubic prostatectomy with the formation of fascial duplication in the elimination of damage to the anterior rectal wall in 2 patients with prostate cancer. Patients with intermediate risk of recurrence and progression according to the D'Amico index. The observation period is 6 and 11 months.Results. Prostatectomy revealed damage to the anterior rectal wall and destruction of the external longitudinal muscular layer of the rectum. The rectal defect was eliminated according to the original method. The duration of the operation is 160 and 140 min. Intraoperative blood loss 350 and 150 ml. The first bowel movement on the 5th day. Removal of the urethral catheter on day 10. The period of hospitalization was 11 and 14 days, no postoperative mortality was noted. No lethal outcomes were noted.Conclusion. A constructively simple surgical technique for the formation of fascial duplication by local tissues in case of intraoperative injury of the rectum during prostatectomy has been developed and implemented into clinical practice.

25 March 2025 in Experimental and Сlinical Urology
Verified
Journal Article
Open access
TFthe Department of Surgical Diseases and Urology of the Omsk State Medical University of the Ministry of Health of the Russian Federation
the Department of Surgical Diseases and Urology of the Omsk State Medical University of the Ministry of Health of the Russian Federation
ATA.YU. Tsukanov
A.YU. Tsukanov
MBM.I. Baypakova
M.I. Baypakova
RORussia City Clinical Perinatal Center; Omsk
Russia City Clinical Perinatal Center; Omsk
VDV.P. Dorofeeva
V.P. Dorofeeva
ISI.O. Snitko
I.O. Snitko
Introduction. Radiation injury of the bladder is a complication after therapeutic irradiation of the pelvic organs. The strategy of pharmacotherapy of such complications is currently unclear due to the small number of studies and unclear pathogenesis. Purpose of the study – to study the effectiveness of the use of bovine bladder polypeptides in modeling radiation injury of the bladder in rats. Materials and methods. An animal model of radiation cystitis was formed by a single irradiation at a dose of 20 Gy with determination of the isocenter on a 3D model. The study used 55 female Wistar rats, which were divided into 5 groups: group 1 – intact, without exposure; group 2 – negative control (irradiation without therapy); group 3 – therapy with Vezusten, starting from the 10th day after irradiation, intramuscularly daily for 10 days, at a dose of 0.056 mg/kg, in a volume of 0.1 ml; Group 4 – administration of Vezusten to intact animals, intramuscularly daily for 10 days, at a dose of 0.056 mg/kg, in a volume of 0.1 ml; Group 5 – «standard therapy» was administered, instillation of a combination of hydrocor- tisone+heparin+lidocaine for 10 days, starting from the 10th day after irradiation. The animals were withdrawn on the 40th day after irradiation. Results. In the achieved model of radiation cystitis, in the group receiving the peptide drug Vezusten, much less damage to the bladder wall was noted (preservation of epithelial stratification, folding, plethora of the submucosal layer), as well as better tolerance of irradiation and the post-radiation period (less pronounced alopecia, minimal skin changes in the places of animal fixation, physiological behavior of the animal). Conclusion. In the achieved experimental model of radiation cystitis in rats, the introduction of regulatory polypeptides of the urinary bladder of cattle (the drug Vezusten) significantly reduced both the clinical manifestations of radiation injury and normalized the morphological picture. Probably, the reparative effect of Vezusten is realized, among other things, due to the normalization of the expression of the paracrine peptide factor TGF-β1, compared to animals without therapy.

27 October 2023 in Ural Medical Journal
Verified
Journal Article
Open access
PDF file
EKE. R. Khayrutdinov
E. R. Khayrutdinov
DGD. G. Gromov
D. G. Gromov
AAA. V. Arablinskiy
A. V. Arablinskiy
IVI. M. Vorontsov
I. M. Vorontsov
OLO. V. Leonov
O. V. Leonov
YIYu. T. Ignatev
Yu. T. Ignatev
Introduction Malignant neoplasms of the liver are one of the most common pathologies in oncology. Chemoembolization of the hepatic artery is currently widely used in the treatment of unresectable liver tumors. Transradial vascular access is actively used in interventional cardiology due to fewer local vascular complications. At the same time, until recently, chemoembolization of the hepatic artery was more often performed via transfemoral vascular access.The aim of the work is a comparative analysis of the results of transradial and transfemoral vascular accesses for the purpose of hepatic artery chemoembolization.Material and methods The data of 69 patients who underwent 212 hepatic artery chemoembolization procedures for malignant neoplasms in the liver were analyzed. The group of transradial access included 107 (50.5 %) interventions, the group of transfemoral access – 105 (49.5 %). The groups were comparable in terms of the main initial clinical and anamnestic data.Results Chemoembolization of the hepatic artery was successfully performed in 98.1 % in the transradial access group and 99 % in the transfemoral access group (p = 1.0). The total duration of intervention, time spent on catheterization of the target artery and radiation exposure were significantly shorter in the transradial access group than in the opposite group. The incidence of local vascular complications was not significantly different between the groups: 11 (10.3 %) and 12 (11.4 %) cases, respectively (p = 0.79). According to the results of patient interviews, the use of transradial access was accompanied by significantly less discomfort associated with the procedure.Discussion Traditionally, embolization of peripheral arteries is performed via transfemoral access, and the total incidence of local vascular complications (large subcutaneous hematomas, false aneurysms, arterovenous fistulas, etc.) is relatively high. According to the results of studies, it is possible to reduce the incidence of local vascular complications without increasing the cost of the procedure by performing the same interventions using transradial access.Conclusion Transradial vascular access has a number of significant advantages over transfemoral access, and therefore can be recommended as a priority for performing hepatic artery chemoembolization.

15 August 2022 in Cancer Urology
Verified
Journal Article
Open access
PDF file
ALA. O. Leonova
A. O. Leonova
EKE. I. Kopyltsov
E. I. Kopyltsov
BAB. Ya. Alekseev
B. Ya. Alekseev
ISI. A. Sikhvardt
I. A. Sikhvardt
YYYu. N. Yurgel
Yu. N. Yurgel
ЮЮЮ. Н. Юргель
Ю. Н. Юргель
Aim. To improve diagnostics and screening of prostate cancer to ensure early detection of malignant tumors.Materials and methods. We analyzed the population size and structure in the region in 2005–2010. The primary diagnostics of prostate cancer in regional healthcare institutions allowed the detection of locally advanced tumors and generalized cancer. Such diagnostic approaches can produce only accidental diagnosis since they lack proper systematization, organization, and control.Results. We have developed and implemented into clinical practice a long-term Program for Prostate Cancer Early Diagnosis and Screening. It includes a diagnostic algorithm for prostate cancer that was modified for clinical use. Screening starts with the PSA blood test performed annually. Patients with PSA level 10 ng/mL should undergo additional diagnostic procedures. The Program implies active use of currently available information technologies to implement a unified routing scheme for cancer patients, execute measures for early cancer diagnosis, and warrant promptness and reliability of the cancer registry.Conclusion. Implementation of the long-term Program for Prostate Cancer Early Diagnosis and Screening will help to improve prostate cancer diagnosis, and, therefore, treatment outcomes.

30 December 2018 in Cancer Urology
Verified
Journal Article
Open access
ISI. A. Sikhvardt
I. A. Sikhvardt
BAB. Ya. Alekseev
B. Ya. Alekseev
OLO. V. Leonov
O. V. Leonov
EKE. I. Kopyltsov
E. I. Kopyltsov
MMM. S. Mazhbich
M. S. Mazhbich
VVV. A. Vodolazskiy
V. A. Vodolazskiy
Objective: to develop and substantiate the method of stabilization of urethrovesical anastomosis with retropubic prostatectomy to improve the results of early recovery of urinary retention.Materials and methods. 58 patients who had undergone radical prostatectomy were enrolled into the prospective study. The patient population was divided into two groups by the blinded randomization. The first control group consists of 29 men who underwent traditional routine surgical treatment. The second main group (29 patients) who underwent novel surgical treatment with making urethrocysteoanastomosis based on original method (Patent for invention № 2559588 from 14 Jul 2015 “Method of propylaxis of urinary incontinence after retropubic prostatectomy”).Results. At the moment of the hospital discharge the urine continence was achieved by the 20.7 % (n = 6) patients from the first group and 48.3 % (n = 14) patients from the second group. During the follow-up period in a month after surgery urine continence was maintained by the 37.9 % (n = 11) patients from the first group and 72.4 % (n = 23) patients from the second group, in three months after surgery — 62.0 % (n = 18) patients from the first group and 79.3 % (n = 23) patients from the second group. After the 6 months follow-up period 75.9 % (n = 22) patients from the first group and 86.2 % (n = 25) patients from the second group maintain urine continence. One-year follow-up period showed urine continence in 89.7 % (n = 26) patients from the first group and 93.1 % (n = 27) patients from the second group Conclusion. The surgical technique developed and introduced into clinical practice made it possible to stabilize urethrocysteoanastomosis, prevent or significantly shorten the incontinence period within the first year after retropubic prostatectomy, and improve the quality of life of patients.